107
A brief introduc.on to current efforts in scien.fic discourse annota.on Anita de Waard Disrup/ve Technology Director, Elsevier Labs also on behalf of HCLS/UU/D2S... hEp://elsatglabs.com/labs/anita Thursday, October 20, 2011

Overview of scientific discourse annotatoin

Embed Size (px)

DESCRIPTION

Presentation held at second Amicus workshop, http://amicus.uvt.nl/amicus_ws2011.htm: "Storytelling in Fairytales and Science:Narrative structure models of scientific communication and folktales"

Citation preview

Page 1: Overview of scientific discourse annotatoin

A  brief  introduc.on  to  current  efforts  in

scien.fic  discourse  annota.on  

Anita  de  Waard

Disrup/ve  Technology  Director,  Elsevier  Labs-­‐  also  on  behalf  of  HCLS/UU/D2S...

hEp://elsatglabs.com/labs/anita  

Thursday, October 20, 2011

Page 2: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

2

Thursday, October 20, 2011

Page 3: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  

2

Thursday, October 20, 2011

Page 4: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2

Thursday, October 20, 2011

Page 5: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

2

Thursday, October 20, 2011

Page 6: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)

2

Thursday, October 20, 2011

Page 7: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

2

Thursday, October 20, 2011

Page 8: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

5.Special  case  of  3&4:  Claim/Evidence  network  (+D2S)

2

Thursday, October 20, 2011

Page 9: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

5.Special  case  of  3&4:  Claim/Evidence  network  (+D2S)

For  each  level:  

2

Thursday, October 20, 2011

Page 10: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

5.Special  case  of  3&4:  Claim/Evidence  network  (+D2S)

For  each  level:  a)Why?  Use  cases  

2

Thursday, October 20, 2011

Page 11: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

5.Special  case  of  3&4:  Claim/Evidence  network  (+D2S)

For  each  level:  a)Why?  Use  cases  

b)What,  by  whom?  Concepts,  ontology,  authors?2

Thursday, October 20, 2011

Page 12: Overview of scientific discourse annotatoin

One  way  of  subdividing  the  field  ofScien/fic  Discourse  Annota/on:

Five  levels  of  markup:  1.Sec/on:  “Discussion”,  ~  several  paragraphs  (+HCLS)

2.Module:  “Research  Ques/on”,  ~  paragraph

3.Statement:  “Hypothesis”,  ~  sentence/clause  (+UU)4.Rela/on:  “Supports”,  ~  hyperlink(En/ty:  “Gene  Name”,  ~  NP)

5.Special  case  of  3&4:  Claim/Evidence  network  (+D2S)

For  each  level:  a)Why?  Use  cases  

b)What,  by  whom?  Concepts,  ontology,  authors?

c) How?  Manual,  automated?   2

Thursday, October 20, 2011

Page 13: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

3

Thursday, October 20, 2011

Page 14: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

3

INTRODUCTION

Thursday, October 20, 2011

Page 15: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

a.Why  mark  up  sec/ons?-­‐ Search:  e.g.  search  for  en//es  in  Methods

-­‐ Visualisa/on:  e.g.  structured  browse  at  sec/on  level

3

INTRODUCTION

Thursday, October 20, 2011

Page 16: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

a.Why  mark  up  sec/ons?-­‐ Search:  e.g.  search  for  en//es  in  Methods

-­‐ Visualisa/on:  e.g.  structured  browse  at  sec/on  level

b.What,  by  whom?-­‐ Background/Contribu/on/Discussion  model  for  CS

-­‐ HCLS:  Ontology  of  Rhetorical  Blocks  (ORB)=  IMRaD  in  OWL

3

INTRODUCTION

Thursday, October 20, 2011

Page 17: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

a.Why  mark  up  sec/ons?-­‐ Search:  e.g.  search  for  en//es  in  Methods

-­‐ Visualisa/on:  e.g.  structured  browse  at  sec/on  level

b.What,  by  whom?-­‐ Background/Contribu/on/Discussion  model  for  CS

-­‐ HCLS:  Ontology  of  Rhetorical  Blocks  (ORB)=  IMRaD  in  OWL

3

INTRODUCTION

Annotation

Thursday, October 20, 2011

Page 18: Overview of scientific discourse annotatoin

1.  Sec/on-­‐level  markup

a.Why  mark  up  sec/ons?-­‐ Search:  e.g.  search  for  en//es  in  Methods

-­‐ Visualisa/on:  e.g.  structured  browse  at  sec/on  level

b.What,  by  whom?-­‐ Background/Contribu/on/Discussion  model  for  CS

-­‐ HCLS:  Ontology  of  Rhetorical  Blocks  (ORB)=  IMRaD  in  OWL

c.Automate?  -­‐ Yes  -­‐[Hovy/Ramakrishnan]

3

INTRODUCTION

Annotation

Thursday, October 20, 2011

Page 19: Overview of scientific discourse annotatoin

HCLS  SciDis:  develop  standards  for  this  markup

4

Thursday, October 20, 2011

Page 20: Overview of scientific discourse annotatoin

2.a.  Module-­‐level  markup:  why?

5

-­‐ BeEer  search:  e.g.  query  inside  ‘Research  ques/on’

-­‐ Ini/al  idea:  content  reuse,  e.g.

-­‐ Write  Methods  sec/ons  once,  import/link  many

-­‐ Different  way  of  crea/ng  a  collec/on  of  scholarly  content:  not  standalone  narra/ve,  but  connected  set  of  modules  

Thursday, October 20, 2011

Page 21: Overview of scientific discourse annotatoin

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 22: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 23: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 24: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 25: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 26: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

-­‐ LiquidPub,  2010:  Structured  Knowledge  Objects  

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 27: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

-­‐ LiquidPub,  2010:  Structured  Knowledge  Objects  

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 28: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

-­‐ LiquidPub,  2010:  Structured  Knowledge  Objects  

-­‐ HCLS:  Medium-­‐grained  structure:  core  narra/ve  components

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 29: Overview of scientific discourse annotatoin

-­‐ Kircz,  ’98:  “a  much  more  radical  approach  would  be  to  [break]  apart  the  linear  text  into  independent  modules,  each  with  its  own  unique  cogni/ve  character.”

-­‐ Harmsze,  ‘00:  modular  model  for  physics  papers

-­‐ LiquidPub,  2010:  Structured  Knowledge  Objects  

-­‐ HCLS:  Medium-­‐grained  structure:  core  narra/ve  components

2.b.  Module-­‐level  markup:  What,  by  whom?  

6

Thursday, October 20, 2011

Page 30: Overview of scientific discourse annotatoin

7

The Story of Goldilocks and the Three Bears

Story Grammar Paper The AXH Domain of Ataxin-1 Mediates Neurodegeneration through Its Interaction with Gfi-1/Senseless Proteins

Once upon a time Time Setting Background The mechanisms mediating SCA1 pathogenesis are still not fully understood, but some general principles have emerged.

a little girl named Goldilocks Characters

Setting

Objects of study the Drosophila Atx-1 homolog (dAtx-1) which lacks a polyQ tract,

She went for a walk in the forest. Pretty soon, she came upon a house.

Location

Setting

Experimental setup

studied and compared in vivo effects and interactions to those of the human protein

She knocked and, when no one answered,

Goal Theme Researchgoal

Gain insight into how Atx-1's function contributes to SCA1 pathogenesis. How these interactions might contribute to the disease process and how they might cause toxicity in only a subset of neurons in SCA1 is not fully understood.she walked right in. Attempt

Theme

Hypothesis Atx-1 may play a role in the regulation of gene expression

At the table in the kitchen, there were three bowls of porridge.

Name Episode 1 Name dAtX-1 and hAtx-1 Induce Similar Phenotypes When Overexpressed in Files

Goldilocks was hungry. Subgoal

Episode 1

Subgoal test the function of the AXH domain

She tasted the porridge from the first bowl.

Attempt

Episode 1

Method overexpressed dAtx-1 in flies using the GAL4/UAS system (Brand and Perrimon, 1993) and compared its effects to those of hAtx-1. This porridge is too hot! she

exclaimed.Outcome

Episode 1

Results Overexpression of dAtx-1 by Rhodopsin1(Rh1)-GAL4, which drives expression in the differentiated R1-R6 photoreceptor cells (Mollereau et al., 2000 and O'Tousa et al., 1985), results in neurodegeneration in the eye, as does overexpression of hAtx-1[82Q]. Although at 2 days after eclosion, overexpression of either Atx-1 does not show obvious morphological changes in the photoreceptor cells

So, she tasted the porridge from the second bowl.

Activity

Episode 1

Data (data not shown),

This porridge is too cold, she said Outcome

Episode 1

Results both genotypes show many large holes and loss of cell integrity at 28 days

So, she tasted the last bowl of porridge.

 Activity

Episode 1

Data (Figures 1B-1D).

Ahhh, this porridge is just right, she said happily and

Outcome

Episode 1

Results Overexpression of dAtx-1 using the GMR-GAL4 driver also induces eye abnormalities. The external structures of the eyes that overexpress dAtx-1 show disorganized ommatidia and loss of interommatidial bristles she ate it all up.  

Episode 1

Data (Figure 1F),

Story  grammar  model  for  science

Thursday, October 20, 2011

Page 31: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?

8

Thursday, October 20, 2011

Page 32: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:

8

Thursday, October 20, 2011

Page 33: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

8

Thursday, October 20, 2011

Page 34: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

8

Thursday, October 20, 2011

Page 35: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

-­‐ Author  creates:  templates.

8

Thursday, October 20, 2011

Page 36: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

-­‐ Author  creates:  templates.-­‐ XPharm,  2001:  modular  text  book  in  pharmacology:

8

Thursday, October 20, 2011

Page 37: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

-­‐ Author  creates:  templates.-­‐ XPharm,  2001:  modular  text  book  in  pharmacology:

8

Thursday, October 20, 2011

Page 38: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

-­‐ Author  creates:  templates.-­‐ XPharm,  2001:  modular  text  book  in  pharmacology:

-­‐ Only  works  if  you  pay  authors!

8

Thursday, October 20, 2011

Page 39: Overview of scientific discourse annotatoin

2.c.  Module-­‐level  markup:  how?-­‐ Automated  recogni/on:  very  difficult:-­‐ How  do  you  know  where  the  boundaries  are?  

-­‐ Even  difficult  for  author  to  iden/fy!  

-­‐ Author  creates:  templates.-­‐ XPharm,  2001:  modular  text  book  in  pharmacology:

-­‐ Only  works  if  you  pay  authors!

-­‐ Mo/f  detec/on  workmight  offer  help?  

8

Thursday, October 20, 2011

Page 40: Overview of scientific discourse annotatoin

3.  Statement-­‐level  markup

9

Thursday, October 20, 2011

Page 41: Overview of scientific discourse annotatoin

3.  Statement-­‐level  markup

9

a.Why?-­‐ Automated  summarisa/on?

-­‐ Towards  claim-­‐evidence  networks

Thursday, October 20, 2011

Page 42: Overview of scientific discourse annotatoin

3.  Statement-­‐level  markup

9

a.Why?-­‐ Automated  summarisa/on?

-­‐ Towards  claim-­‐evidence  networks

b.How,  by  whom?  -­‐ Comparison  of  three  groups:  1.Liakata  et  al.:  CoreSC2.Ananiadou  et  al.:  Metaknowledge  annota/on3.De  Waard/Pander  Maat:  Discourse  Segment  Types

-­‐ Annotated  three  texts:  compare  schemes,  levels,  annota/on  overlap

Thursday, October 20, 2011

Page 43: Overview of scientific discourse annotatoin

3.1  Liakata  et  al.:  Core-­‐Scien/fic  Concepts  (CoreSC)  Annota/on  Scheme

s

Thursday, October 20, 2011

Page 44: Overview of scientific discourse annotatoin

3.1  Liakata  et  al.:  Core-­‐Scien/fic  Concepts  (CoreSC)  Annota/on  Scheme

Three-­‐layer,  ontology-­‐mo/vated  annota/on  scheme  for  sentence  annota/on,  which  views  a  paper  as  the  humanly  readable  representa0on  of  a  scien0fic  inves0ga0on:  [45-­‐page  guideline:  Liakata  &  Soldatova  2008]  -­‐ 1st  layer:  Core  Scien4fic  Concepts  (CoreSCs):  Hypothesis,  Mo/va/on,  Goal,  Object,  Background,  Method,  Experiment,  Model,  Observa/on,  Result,  Conclusion  

-­‐ 2nd  layer:  Proper4es  of  CoreSCs.  Novelty  (New/Old)  and  Advantage  (advantage/disadvantage)

-­‐ 3rd  layer:  Concept  Iden4fiers:  linking  sentences  together  which  refer  to  the  same  instance  of  a  CoreSC

s

Thursday, October 20, 2011

Page 45: Overview of scientific discourse annotatoin

3.1  CoreSC  Annota/on  tool:

Thursday, October 20, 2011

Page 46: Overview of scientific discourse annotatoin

3.1  CoreSC  Annota/on  tool:

• Automated  annota/on  with  CoreSC  system  well  underway!

Thursday, October 20, 2011

Page 47: Overview of scientific discourse annotatoin

Class  /  Type(Grounded  to  an  event  

ontology)

Knowledge  Type•  Inves4ga4on•  Observa4on•  Analysis•  General

Manner•  High•  Low•  Neutral

Certainty  Level•L3•L2•L1

Polarity•  Nega4ve•  Posi4ve

Source•  Other•  Current

Par4cipants•  Theme(s)•  Actor(s)

Bio-­‐Event(Centred  on  an  Event  

Trigger)

3.2.  Ananiadou  et  al:  Metaknowledge  annota/on:

Thursday, October 20, 2011

Page 48: Overview of scientific discourse annotatoin

S3 = These results suggest that Y has no effect on expression of X

EventKnowledge

Type

Certainty

Level

Lexical  

PolarityManner Source

E1 General L3 Posi4ve Neutral Current

E2 Analysis L2 Nega4ve Neutral Current

3.2  Example  of  Metaknowledge  annota/on:

Thursday, October 20, 2011

Page 49: Overview of scientific discourse annotatoin

S3 = These results suggest that Y has no effect on expression of X

EventKnowledge

Type

Certainty

Level

Lexical  

PolarityManner Source

E1 General L3 Posi4ve Neutral Current

E2 Analysis L2 Nega4ve Neutral Current

3.2  Example  of  Metaknowledge  annota/on:

Thursday, October 20, 2011

Page 50: Overview of scientific discourse annotatoin

S3 = These results suggest that Y has no effect on expression of X

EventKnowledge

Type

Certainty

Level

Lexical  

PolarityManner Source

E1 General L3 Posi4ve Neutral Current

E2 Analysis L2 Nega4ve Neutral Current

3.2  Example  of  Metaknowledge  annota/on:

Thursday, October 20, 2011

Page 51: Overview of scientific discourse annotatoin

S3 = These results suggest that Y has no effect on expression of X

EventKnowledge

Type

Certainty

Level

Lexical  

PolarityManner Source

E1 General L3 Posi4ve Neutral Current

E2 Analysis L2 Nega4ve Neutral Current

• Manual  annota/on  underway  of  the  GENIA  event  corpus  (1000  MEDLINE  abstracts)

3.2  Example  of  Metaknowledge  annota/on:

Thursday, October 20, 2011

Page 52: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 53: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 54: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 55: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 56: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 57: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 58: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

Implication

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 59: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

Implication

Goal

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 60: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

Implication

Goal

Reg-Implication

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 61: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

Implication

Goal

Reg-Implication

Conceptual knowledge

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 62: Overview of scientific discourse annotatoin

Both seminomas and the EC component of nonseminomas share features with ES cells. To exclude that the detection of miR-371-3 merely reflects its expression pattern in ES cells, we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004). In many of the m i R - 3 7 1 - 3 e x p r e s s i n g s e m i n o m a s a n d nonseminomas, miR-302a-d was undetectable (Figs S7 and S8), suggesting that miR-371-3 expression is a selective event during tumorigenesis.

Both seminomas and the EC component of nonseminomas share features with ES cells.To exclude thatthe detection of miR-371-3 merely reflects its expression pattern in ES cells,we tested by RPA miR-302a-d, another ES cells-specific miRNA cluster (Suh et al, 2004).In many of the miR-371-3 expressing seminomas and nonseminomas, miR-302a-d was undetectable (Figs S7 and S8),suggesting thatmiR-371-3 expression is a selective event during tumorigenesis.

Fact

Hypothesis

Method

Result

Implication

Goal

Reg-Implication

Conceptual knowledge

ExperimentalEvidence

3.3  de  Waard/Pander  Maat:  Discourse  Segment  Types

Thursday, October 20, 2011

Page 63: Overview of scientific discourse annotatoin

3.3  Iden/fica/on  of  DSTs:

15

Thursday, October 20, 2011

Page 64: Overview of scientific discourse annotatoin

3.3  Iden/fica/on  of  DSTs:-­‐ Verb  form:  tense,  e.g.  -­‐ Concepts  in  ‘state’  (gnomic)  present:‘Dopaminergic  innerva/on  plays  a  major  role  in  the  control  of  mood  and  its  perturba/on’  

-­‐ Experiments  in  ‘event’  past:  ‘Four  out  of  seven  cell  lines  expressed  this  cluster’

15

Thursday, October 20, 2011

Page 65: Overview of scientific discourse annotatoin

3.3  Iden/fica/on  of  DSTs:-­‐ Verb  form:  tense,  e.g.  -­‐ Concepts  in  ‘state’  (gnomic)  present:‘Dopaminergic  innerva/on  plays  a  major  role  in  the  control  of  mood  and  its  perturba/on’  

-­‐ Experiments  in  ‘event’  past:  ‘Four  out  of  seven  cell  lines  expressed  this  cluster’

-­‐ Seman4c  verb  class:  -­‐ Research  verbs  (Inves/ga/on,  Predic/on,  Procedure,  Observa/on,  Interpreta/on)

-­‐ Discourse  verbs  -­‐ Proper/es  and  rela/onships  -­‐  between  things  and  concepts

15

Thursday, October 20, 2011

Page 66: Overview of scientific discourse annotatoin

3.3  Iden/fica/on  of  DSTs:-­‐ Verb  form:  tense,  e.g.  -­‐ Concepts  in  ‘state’  (gnomic)  present:‘Dopaminergic  innerva/on  plays  a  major  role  in  the  control  of  mood  and  its  perturba/on’  

-­‐ Experiments  in  ‘event’  past:  ‘Four  out  of  seven  cell  lines  expressed  this  cluster’

-­‐ Seman4c  verb  class:  -­‐ Research  verbs  (Inves/ga/on,  Predic/on,  Procedure,  Observa/on,  Interpreta/on)

-­‐ Discourse  verbs  -­‐ Proper/es  and  rela/onships  -­‐  between  things  and  concepts

-­‐ Modality  -­‐ Types:  Source  {Author,  others,  unknown},  Basis  {Data,  Reasoning,  0},  Value  {Certain,  probable,  possible,  unknown}

-­‐ Markers:  Modal  aux,  verb  class  Interpreta/on,  epistemic  adverbs15

Thursday, October 20, 2011

Page 67: Overview of scientific discourse annotatoin

3.  Same  Statement  annotated  three  ways:

Thursday, October 20, 2011

Page 68: Overview of scientific discourse annotatoin

3.  Same  Statement  annotated  three  ways:CoreSC:<annotationART atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None">Here we show that BOB.1/OBF.1 regulates Btk gene expression.</annotationART> BioEvent/MetaKnowledge:<sentence id="S6">Here we show that <term id="T13" sem="Protein_family_or_group">

<gene-or-gene-product id="G9">BOB.1</gene-or-gene-product>/<gene-or-gene-product id="G10">OBF.1</gene-or-gene-product>

</term> regulates <term id="T14" sem="Biological_process">

<term id="T15" sem="DNA_domain_or_region"><gene-or-gene-product id="G11">Btk

</gene-or-gene-product> gene</term> expression

</term>. </sentence>

Discourse Segments:<segment segID ="286" section = "D" segtype = "RegImplication">Here we show that</segment><segment segID ="287" section = "D" segtype = "Implication">

Thursday, October 20, 2011

Page 69: Overview of scientific discourse annotatoin

3.  Same  Statement  annotated  three  ways:CoreSC:<annotationART atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None">Here we show that BOB.1/OBF.1 regulates Btk gene expression.</annotationART> BioEvent/MetaKnowledge:<sentence id="S6">Here we show that <term id="T13" sem="Protein_family_or_group">

<gene-or-gene-product id="G9">BOB.1</gene-or-gene-product>/<gene-or-gene-product id="G10">OBF.1</gene-or-gene-product>

</term> regulates <term id="T14" sem="Biological_process">

<term id="T15" sem="DNA_domain_or_region"><gene-or-gene-product id="G11">Btk

</gene-or-gene-product> gene</term> expression

</term>. </sentence>

Discourse Segments:<segment segID ="286" section = "D" segtype = "RegImplication">Here we show that</segment><segment segID ="287" section = "D" segtype = "Implication">BOB.1/OBF.1 regulates Btk gene expression.</segment> Thursday, October 20, 2011

Page 70: Overview of scientific discourse annotatoin

3.  Same  Statement  annotated  three  ways:CoreSC:<annotationART atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None">Here we show that BOB.1/OBF.1 regulates Btk gene expression.</annotationART> BioEvent/MetaKnowledge:<sentence id="S6">Here we show that <term id="T13" sem="Protein_family_or_group">

<gene-or-gene-product id="G9">BOB.1</gene-or-gene-product>/<gene-or-gene-product id="G10">OBF.1</gene-or-gene-product>

</term> regulates <term id="T14" sem="Biological_process">

<term id="T15" sem="DNA_domain_or_region"><gene-or-gene-product id="G11">Btk

</gene-or-gene-product> gene</term> expression

</term>. </sentence>

Discourse Segments:<segment segID ="286" section = "D" segtype = "RegImplication">Here we show that</segment><segment segID ="287" section = "D" segtype = "Implication">BOB.1/OBF.1 regulates Btk gene expression.</segment> Thursday, October 20, 2011

Page 71: Overview of scientific discourse annotatoin

Who Why What How

Liakata:  CoreSC Iden/fy  main  components  of  scien/fic  inves/ga/on  for  machine  learning

Sentence Manual  corpus,  automated  annota/on  tools  -­‐  working  on  automated  detec/on

Ananiadou:  MetaKnowledge/BioEvents

Enhance  informa/on  extrac/on  for  biomedical  texts  to  enable  metadiscourse  annota/on

Events  (intra-­‐senten/al):  can  be  several  per  sentence,  or  one  in  more  sentences

Manual  corpus,  working  on  automated  detec/on

de  Waard:Discourse  Segment  Types

Iden/fy  mechanisms  of  conveying  (epistemic)  knowledge  in  scien/fic    discourse

Clause Manual,  ideas  (but  no  real  plans!)  for  automated  iden/fica/on

3.  Comparing  statement-­‐level  annota/on  models

Thursday, October 20, 2011

Page 72: Overview of scientific discourse annotatoin

4.  Rela.ons

a.Why?-­‐ Argumenta/on  visualisa/on

b.What,  by  whom?  -­‐ Harmsze  (1999):  Ontology  of  content  rela/onships

-­‐ IBIS,  ClaiMaker  (2001)

-­‐ Diligent  argumenta/on  ontology  (2005)  

-­‐ SALT:  RST  (2007)

-­‐ SWAN  (2010)

c.How?  -­‐ So  far:  Manually 18

Thursday, October 20, 2011

Page 73: Overview of scientific discourse annotatoin

4.  Rela.ons

a.Why?-­‐ Argumenta/on  visualisa/on

b.What,  by  whom?  -­‐ Harmsze  (1999):  Ontology  of  content  rela/onships

-­‐ IBIS,  ClaiMaker  (2001)

-­‐ Diligent  argumenta/on  ontology  (2005)  

-­‐ SALT:  RST  (2007)

-­‐ SWAN  (2010)

c.How?  -­‐ So  far:  Manually 18

Thursday, October 20, 2011

Page 74: Overview of scientific discourse annotatoin

4.  Rela.ons

a.Why?-­‐ Argumenta/on  visualisa/on

b.What,  by  whom?  -­‐ Harmsze  (1999):  Ontology  of  content  rela/onships

-­‐ IBIS,  ClaiMaker  (2001)

-­‐ Diligent  argumenta/on  ontology  (2005)  

-­‐ SALT:  RST  (2007)

-­‐ SWAN  (2010)

c.How?  -­‐ So  far:  Manually 18

Thursday, October 20, 2011

Page 75: Overview of scientific discourse annotatoin

4.  Rela.ons

a.Why?-­‐ Argumenta/on  visualisa/on

b.What,  by  whom?  -­‐ Harmsze  (1999):  Ontology  of  content  rela/onships

-­‐ IBIS,  ClaiMaker  (2001)

-­‐ Diligent  argumenta/on  ontology  (2005)  

-­‐ SALT:  RST  (2007)

-­‐ SWAN  (2010)

c.How?  -­‐ So  far:  Manually 18

Thursday, October 20, 2011

Page 76: Overview of scientific discourse annotatoin

4.  Rela.ons

a.Why?-­‐ Argumenta/on  visualisa/on

b.What,  by  whom?  -­‐ Harmsze  (1999):  Ontology  of  content  rela/onships

-­‐ IBIS,  ClaiMaker  (2001)

-­‐ Diligent  argumenta/on  ontology  (2005)  

-­‐ SALT:  RST  (2007)

-­‐ SWAN  (2010)

c.How?  -­‐ So  far:  Manually 18

Thursday, October 20, 2011

Page 77: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

Thursday, October 20, 2011

Page 78: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?

Thursday, October 20, 2011

Page 79: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

Thursday, October 20, 2011

Page 80: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?

Thursday, October 20, 2011

Page 81: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

Thursday, October 20, 2011

Page 82: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

Thursday, October 20, 2011

Page 83: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

Thursday, October 20, 2011

Page 84: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

Thursday, October 20, 2011

Page 85: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

Thursday, October 20, 2011

Page 86: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

Thursday, October 20, 2011

Page 87: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

-­‐ Nanopublica/ons  +  SWAN,  2011

Thursday, October 20, 2011

Page 88: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

-­‐ Nanopublica/ons  +  SWAN,  2011

c.How?  

Thursday, October 20, 2011

Page 89: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

-­‐ Nanopublica/ons  +  SWAN,  2011

c.How?  

-­‐ So  far:  manuallyThursday, October 20, 2011

Page 90: Overview of scientific discourse annotatoin

5.Claim-­‐Evidence  Networks  (statement  +  rela/ons)

19

a.Why?Show  argumenta/on  across  body  of  work

b.What,  by  whom?-­‐ Buckingham  Shum,  1999

-­‐ SWAN:  Clark,  Ciccarese  et  al.,  2005

-­‐ Nanopublica/ons:  Mons,  2010

-­‐ Nanopublica/ons  +  SWAN,  2011

c.How?  

-­‐ So  far:  manuallyThursday, October 20, 2011

Page 91: Overview of scientific discourse annotatoin

20

A. Philips’ Electronic Patient Records B. Elsevier-published Clinical Guideline

C. Elsevier (or other publisher’s) Research Report or Data

D2S  Use  case:  Claim-­‐Evidence  Network  in  Medicine

Thursday, October 20, 2011

Page 92: Overview of scientific discourse annotatoin

20

A. Philips’ Electronic Patient Records B. Elsevier-published Clinical Guideline

C. Elsevier (or other publisher’s) Research Report or Data

Step 1: Patient data + diagnosis link to Guideline recommendation

D2S  Use  case:  Claim-­‐Evidence  Network  in  Medicine

Thursday, October 20, 2011

Page 93: Overview of scientific discourse annotatoin

20

A. Philips’ Electronic Patient Records B. Elsevier-published Clinical Guideline

C. Elsevier (or other publisher’s) Research Report or Data

Step 1: Patient data + diagnosis link to Guideline recommendation

Step 2: Guideline recommendation links to evidence in report or data

D2S  Use  case:  Claim-­‐Evidence  Network  in  Medicine

Thursday, October 20, 2011

Page 94: Overview of scientific discourse annotatoin

20

A. Philips’ Electronic Patient Records B. Elsevier-published Clinical Guideline

C. Elsevier (or other publisher’s) Research Report or Data

Step 1: Patient data + diagnosis link to Guideline recommendation

Step 2: Guideline recommendation links to evidence in report or data

D2S  Use  case:  Claim-­‐Evidence  Network  in  Medicine

Related  HCLS  Use  Case:  Accelerate  uptake  of  medical  research  on  drug-­‐drug  interac/on  in  product  inserts

Thursday, October 20, 2011

Page 95: Overview of scientific discourse annotatoin

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 96: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 97: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 98: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 99: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 100: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 101: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

Thursday, October 20, 2011

Page 102: Overview of scientific discourse annotatoin

Why What/Who How

Sec/on Search,  UI ABCDE,  ORB/HCLSAutomated!  

Publisher  helps?  

Module Content  reuseHarmsze/Kircz,  LiquidPub,  

HCLSManual:  templates

Statement Summaries;  towards  networks

Teufel,  Ananiadou,  Liakata,  UU

Working  towards  automated  detec/on

Rela/ons NetworksSALT,  ScholOnto,  Diligent,  

SWANManual:  some  tools,  never  took  off...

Claim/Evidence

Argumenta/on  networks

 ScholOnto,  SWAN,  Nanopublica/ons,  D2S

Manual-­‐  towards  automa/on?  

Five  levels  of  scien/fic  discourse  annota/on

21

MoFfs?  

Thursday, October 20, 2011

Page 103: Overview of scientific discourse annotatoin

Ques.ons:

22

Thursday, October 20, 2011

Page 104: Overview of scientific discourse annotatoin

Ques.ons:

22

Scien/fic  discourse  -­‐>  fairy  tales:  how  can  we  transfer  knowledge  here  to  scien/fic  discourse  community?  

Thursday, October 20, 2011

Page 105: Overview of scientific discourse annotatoin

Ques.ons:

22

Scien/fic  discourse  -­‐>  fairy  tales:  how  can  we  transfer  knowledge  here  to  scien/fic  discourse  community?  

Issue:  Scien/sts  do  not  like  being  told  that  they  write  fairy  tales!

Thursday, October 20, 2011

Page 106: Overview of scientific discourse annotatoin

Ques.ons:

22

Scien/fic  discourse  -­‐>  fairy  tales:  how  can  we  transfer  knowledge  here  to  scien/fic  discourse  community?  

Issue:  Scien/sts  do  not  like  being  told  that  they  write  fairy  tales!

Fairy  tales  -­‐>  scien/fic  discourse:  is  anyone  here/in  this  community  interested  in  working  on  inter-­‐domain  transfer  of  tools,  technologies  and  theories?

Thursday, October 20, 2011

Page 107: Overview of scientific discourse annotatoin

Ques.ons:

22

Scien/fic  discourse  -­‐>  fairy  tales:  how  can  we  transfer  knowledge  here  to  scien/fic  discourse  community?  

Issue:  Scien/sts  do  not  like  being  told  that  they  write  fairy  tales!

Fairy  tales  -­‐>  scien/fic  discourse:  is  anyone  here/in  this  community  interested  in  working  on  inter-­‐domain  transfer  of  tools,  technologies  and  theories?

Anita  de  Waard,  [email protected]  

-­‐HCLS:  hEp://www.w3.org/wiki/HCLSIG/SWANSIOC

-­‐UU:  hEp://elsatglabs.com/labs/anita  

-­‐D2S:  hEp://www.data2seman/cs.org

Thursday, October 20, 2011